Hookipa Pharma Inc. Stock News

Hookipa Pharma is conducting a call on 04/25/24 to share lead asset HB-200's pivotal trial design.  A Phase 2a clinical update is due in 2Q'24. The company's shares closed at $0.733, with a valuation

HOOKIPA Pharma Inc. (HOOK) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.17 per share a year ago.

HOOKIPA Pharma Inc. (HOOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BK, HCA and HOOK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 2, 2023.

Hookipa Pharma (NASDAQ: HOOK ) stock is on the rise Thursday as investors react to news of a share purchase agreement with Gilead Sciences (NASDAQ: GILD ). According to a filing with the Securities a

Whether you're looking at the “ Magnificent Seven stocks ,” or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week wit

NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavi

Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.

NEW YORK and VIENNA, Austria, Sept. 06, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenav

NEW YORK and VIENNA, Austria, Aug. 03, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavi

This week has seen the stock market flip-flop, including the volatile world of penny stocks. Investors, especially those interested in high-risk, high-reward low-priced stocks, are attentively trackin

HOOKIPA Pharma Inc. (HOOK) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.40 per share a year ago.

NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir

NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir

NEW YORK and VIENNA, Austria, April 26, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenav